Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Assertio Therapeutics and keeping the price target at $3.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Naz Rahman has given his Buy rating due to a combination of factors, primarily driven by Assertio Therapeutics’ impressive third-quarter performance. The company reported revenues significantly exceeding expectations, largely due to the strategic sale of two quarters’ worth of Rolvedon inventory to wholesalers. This move was made to ensure supply availability during a packaging transition, highlighting Assertio’s proactive management approach.
Furthermore, the appointment of a new CEO with extensive experience in oncology commercialization adds a promising dimension to Assertio’s strategic outlook. The new leadership is expected to leverage this expertise to optimize Rolvedon’s market presence and potentially pursue synergistic acquisitions in the oncology space. Despite anticipated short-term cash balance reductions, Assertio’s strong positioning and undervaluation relative to peers suggest potential for transformative growth, supporting Naz Rahman’s positive outlook on the stock.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.